{"slideshow_credits": null, "snippet": "Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker.", "abstract": "Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}, {"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 2, "organization": ""}], "original": "By ANDREW POLLACK and CHAD BRAY"}, "web_url": "http://dealbook.nytimes.com/2014/04/07/mallinckrodt-to-buy-californias-questcor-for-5-6-billion/", "lead_paragraph": null, "headline": {"main": "Mallinckrodt Pharmaceuticals to Buy Questcor for $5.6 Billion", "print_headline": "Mallinckrodt Pharmaceuticals to Buy Questcor for $5.6 Billion ", "kicker": "DealBook"}, "_id": "53429bdb38f0d82e0d98e169", "word_count": "733", "multimedia": [{"height": 126, "url": "images/2014/04/08/business/dbpix-drug3/dbpix-drug3-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/04/08/business/dbpix-drug3/dbpix-drug3-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 75, "url": "images/2014/04/08/business/dbpix-drug3/dbpix-drug3-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/04/08/business/dbpix-drug3/dbpix-drug3-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-04-07T08:33:02Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Bailey, Don M", "rank": "1"}, {"name": "glocations", "value": "San Diego (Calif)", "rank": "4"}, {"name": "glocations", "value": "Dublin (Ireland)", "rank": "3"}, {"name": "glocations", "value": "California", "rank": "2"}, {"name": "glocations", "value": "Anaheim (Calif)", "rank": "1"}, {"name": "organizations", "value": "Justice Department", "rank": "5"}, {"name": "organizations", "value": "Latham & Watkins LLP", "rank": "6"}, {"name": "organizations", "value": "Novartis AG", "rank": "8"}, {"name": "organizations", "value": "Mallinckrodt Pharmaceuticals", "rank": "7"}, {"name": "organizations", "value": "Questcor Pharmaceuticals Incorporated", "rank": "9"}, {"name": "organizations", "value": "Cadence Pharmaceuticals Inc", "rank": "2"}, {"name": "organizations", "value": "Centerview Partners", "rank": "3"}, {"name": "organizations", "value": "Chronic Disease Fund", "rank": "4"}, {"name": "organizations", "value": "Securities and Exchange Commission", "rank": "10"}, {"name": "organizations", "value": "Wachtell Lipton Rosen & Katz", "rank": "11"}, {"name": "organizations", "value": "Barclays PLC", "rank": "1"}, {"name": "subject", "value": "Boards of Directors", "rank": "3"}, {"name": "subject", "value": "Autoimmune Diseases", "rank": "2"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": "5"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "4"}, {"name": "subject", "value": "Stocks and Bonds", "rank": "7"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "6"}, {"name": "subject", "value": "Acthar (Drug)", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}